Live Breaking News & Updates on Qilu Pharmaceutical Co

Stay updated with breaking news from Qilu pharmaceutical co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co. Ltd. announced that the first patient has been treated in Qilu?s Phase 2 trial in China evaluating LSTA1 , Lisata?s lead product candidate, in. ....

Hong Kong , Qilu Pharmaceutical Co , Lisata Therapeutics Inc , Lisata Therapeutics , Qilu Pharmaceutical , Greater China , Qilu Phase , License Agreement ,

Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances

/PRNewswire/ The "Biosimilar Monoclonal Antibodies Global Market Report 2024" has been added to ResearchAndMarkets.com s offering. The expansion of the. ....

United States , Laura Wood , Coherus Biosciences , Mabpharm Limitied , Aprogen Biologics , Reliance Life Sciences , Xentria Inc , Qilu Pharmaceutical Co , Office Hours Call , E St Office Hours Call , Reddy Laboratories Ltd , Celltrion Inc , Lazuline Biotech Private , Chiatai Tianqing Pharmaceutical Group Co , Genor Biopharma Co , Epygen Biotech Pvt Ltd , Bio Rad Laboratories Inc , Yl Biologics Ltd , Biocon Biologics Ltd , Torrent Pharmaceuticals Ltd , Co Ltd , Intas Pharmaceuticals , Amgen Inc , Samsung Bioepis Co , Abxis Corp , Hisun Pharmaceuticals ,

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

/PRNewswire/ On January 29th, the results of the phase II study on Qilu Pharmaceutical s novel anticancer drug iparomlimab and tuvonralimab (QL1706) were. ....

Li Zhang , Sun Yat Sen University Cancer Center , Qilu Pharmaceutical Co Ltd , Qilu Pharmaceutical , Signal Transduction , Targeted Therapy , Qilu Pharmaceutical Co ,

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology

/PRNewswire/ The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line. ....

Shi Yuankai , China National Medical Products Administration , Qilu Pharmaceutical Co Ltd , Qilu Pharmaceutical , Thoracic Oncology , International Association , Lung Cancer , Cancer Hospital , Chinese Academy , Medical Sciences , Independent Review Committee , Qilu Pharmaceutical Co ,

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

/PRNewswire/ During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest. ....

Lin Shen , Qilu Pharmaceutical Co Ltd , Oncology Congress , University Cancer Hospital , Qilu Pharmaceutical , Professor Lin Shen , Peking University Cancer , Qilu Pharmaceutical Co ,